Quantitative High-Throughput Profiling of Environmental Chemicals and Drugs that Modulate Farnesoid X Receptor

[1]  V. Hsu,et al.  Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone. , 2014, Biochimica et biophysica acta.

[2]  David M. Reif,et al.  Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway , 2014, Scientific Reports.

[3]  C. Bouchard,et al.  Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. , 2014, JAMA.

[4]  V. Tremaroli,et al.  FXR is a molecular target for the effects of vertical sleeve gastrectomy , 2014, Nature.

[5]  M. Trauner,et al.  Bile acid receptors as targets for drug development , 2014, Nature Reviews Gastroenterology &Hepatology.

[6]  B. Bhushan,et al.  GASTROINTESTINAL , HEPATOBILIARY , AND PANCREATIC PATHOLOGY Role of Bile Acids in Liver Injury and Regeneration following Acetaminophen Overdose , 2013 .

[7]  James B. Mitchell,et al.  Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity , 2013, Nature Communications.

[8]  Ruili Huang,et al.  The Tox21 robotic platform for the assessment of environmental chemicals--from vision to reality. , 2013, Drug discovery today.

[9]  Taosheng Chen,et al.  Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery. , 2013, Bioorganic & medicinal chemistry.

[10]  Yong Li,et al.  The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism , 2013, Nature Communications.

[11]  C. Austin,et al.  Improving the Human Hazard Characterization of Chemicals: A Tox21 Update , 2013, Environmental health perspectives.

[12]  M. Miyazaki,et al.  Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (−/−) Mice , 2012, Journal of Pharmacology and Experimental Therapeutics.

[13]  Barbara Gross,et al.  Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease , 2012, Journal of Lipid Research.

[14]  A. Parkhomenko,et al.  Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. , 2012, International journal of cardiology.

[15]  Manfred Schubert-Zsilavecz,et al.  Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. , 2012, Future medicinal chemistry.

[16]  Chen-Chang Yang.  Acute human toxicity of macrocyclic lactones. , 2012, Current pharmaceutical biotechnology.

[17]  G. Bifulco,et al.  Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis , 2012, PloS one.

[18]  P. Gresele,et al.  Anti-platelet therapy: phosphodiesterase inhibitors. , 2011, British journal of clinical pharmacology.

[19]  N. Bander,et al.  Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. , 2011, Cancer research.

[20]  Stephen C. West,et al.  DNA interstrand crosslink repair and cancer , 2011, Nature Reviews Cancer.

[21]  Ruili Huang,et al.  Chemical Genomics Profiling of Environmental Chemical Modulation of Human Nuclear Receptors , 2011, Environmental health perspectives.

[22]  Ruili Huang,et al.  The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.

[23]  Jinming Yu,et al.  Abnormal glucose regulation in pyrethroid pesticide factory workers. , 2011, Chemosphere.

[24]  Ruili Huang,et al.  Identification of Clinically Used Drugs That Activate Pregnane X Receptors , 2011, Drug Metabolism and Disposition.

[25]  Franz Schuler,et al.  Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. , 2011, Bioorganic & medicinal chemistry letters.

[26]  C. Keller,et al.  IGF-1 receptor inhibition by picropodophyllin in medulloblastoma. , 2010, Biochemical and biophysical research communications.

[27]  Yanqiao Zhang,et al.  Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity. , 2010, Molecular endocrinology.

[28]  Xiaodong Wang,et al.  Beta tubulin affects the aryl hydrocarbon receptor function via an Arnt-mediated mechanism. , 2010, Biochemical pharmacology.

[29]  S. Kullman,et al.  Exposure to the synthetic FXR agonist GW4064 causes alterations in gene expression and sublethal hepatotoxicity in eleutheroembryo medaka (Oryzias latipes). , 2010, Toxicology and applied pharmacology.

[30]  A. Moschetta,et al.  Deciphering the nuclear bile acid receptor FXR paradigm , 2010, Nuclear receptor signaling.

[31]  P. V. Balaji,et al.  Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine , 2010, BMC Cancer.

[32]  S. Fiorucci,et al.  Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. , 2009, Trends in pharmacological sciences.

[33]  K. Horie-Inoue,et al.  Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. , 2009, Cancer research.

[34]  M. Ebert,et al.  Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid–induced liver hypertrophy , 2009, Hepatology.

[35]  Stefan Westin,et al.  Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). , 2009, Journal of medicinal chemistry.

[36]  D. Moore,et al.  FXR: a metabolic regulator and cell protector , 2008, Cell Research.

[37]  Ida M. Washington,et al.  Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouse. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[38]  Wendong Huang,et al.  FXR, a target for different diseases. , 2008, Histology and histopathology.

[39]  Z. Dvořák,et al.  Expression, protein stability and transcriptional activity of retinoic acid receptors are affected by microtubules interfering agents and all-trans-retinoic acid in primary rat hepatocytes , 2007, Molecular and Cellular Endocrinology.

[40]  W. Frishman.  Calcium Channel Blockers: Differences Between Subclasses , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[41]  Teuvo Kohonen,et al.  Self-organizing neural projections , 2006, Neural Networks.

[42]  B. Staels,et al.  The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[43]  S. Mani,et al.  Activation of the Steroid and Xenobiotic Receptor (Human Pregnane X Receptor) by Nontaxane Microtubule-Stabilizing Agents , 2005, Clinical Cancer Research.

[44]  A. Roda,et al.  Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor. , 2005, Biochemical pharmacology.

[45]  K. Houck,et al.  The Hypolipidemic Natural Product Guggulsterone Is a Promiscuous Steroid Receptor Ligand , 2005, Molecular Pharmacology.

[46]  C. Handschin,et al.  Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. , 2005, Archives of biochemistry and biophysics.

[47]  J. A. Vale,et al.  Poisoning due to Pyrethroids , 2005, Toxicological reviews.

[48]  D. Rader,et al.  Molecular Link Between Bile Acid and Lipid and Glucose Metabolism , 2005 .

[49]  Jennifer M Harrell,et al.  Evidence for Glucocorticoid Receptor Transport on Microtubules by Dynein* , 2004, Journal of Biological Chemistry.

[50]  Vincent Laudet,et al.  Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.

[51]  P. Soubrié,et al.  SR147778 [5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a New Potent and Selective Antagonist of the CB1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization , 2004, Journal of Pharmacology and Experimental Therapeutics.

[52]  F. Zunino,et al.  Gimatecan, a novel camptothecin with a promising preclinical profile , 2004, Anti-cancer drugs.

[53]  N. de Pedro,et al.  The Farnesoid X Receptor Controls Gene Expression in a Ligand- and Promoter-selective Fashion* , 2004, Journal of Biological Chemistry.

[54]  P. Soubrié,et al.  carboxamide ] , a New Potent and Selective Antagonist of the CB 1 Cannabinoid Receptor : Biochemical and Pharmacological Characterization , 2004 .

[55]  Roberto Pellicciari,et al.  Structural basis for bile acid binding and activation of the nuclear receptor FXR. , 2003, Molecular cell.

[56]  S. Wright,et al.  Guggulsterone Is a Farnesoid X Receptor Antagonist in Coactivator Association Assays but Acts to Enhance Transcription of Bile Salt Export Pump* , 2003, The Journal of Biological Chemistry.

[57]  K. Nakashiro,et al.  Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells. , 2003, Oral oncology.

[58]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[59]  D. Mangelsdorf,et al.  A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR , 2002, Science.

[60]  J. Snyder,et al.  The binding conformation of Taxol in β-tubulin: A model based on electron crystallographic density , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. Wainwright,et al.  Acridine-a neglected antibacterial chromophore. , 2001, The Journal of antimicrobial chemotherapy.

[62]  R. Geller,et al.  Calcium channel blocker ingestions in children. , 2000, The American journal of emergency medicine.

[63]  L. Moore,et al.  Identification of a chemical tool for the orphan nuclear receptor FXR. , 2000, Journal of medicinal chemistry.

[64]  H Fang,et al.  The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[65]  D. Ray,et al.  Pyrethroid Insecticides: Poisoning Syndromes, Synergies, and Therapy , 2000, Journal of toxicology. Clinical toxicology.

[66]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[67]  J. Wolff,et al.  Localization of the Vinblastine-binding Site on β-Tubulin* , 1996, The Journal of Biological Chemistry.

[68]  J. Wolff,et al.  Localization of the vinblastine-binding site on beta-tubulin. , 1996, The Journal of biological chemistry.

[69]  G. Kaiser,et al.  Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. , 1995, American journal of veterinary research.

[70]  Jasmine Chen,et al.  Identification of a nuclear receptor that is activated by farnesol metabolites , 1995, Cell.

[71]  M. S. Orr,et al.  Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[72]  H. Spiller,et al.  A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. , 1993, Annals of emergency medicine.

[73]  R. Prichard,et al.  Interaction of benzimidazole anthelmintics with Haemonchus contortus tubulin: binding affinity and anthelmintic efficacy. , 1991, Experimental parasitology.

[74]  S B Hastie,et al.  Interactions of colchicine with tubulin. , 1991, Pharmacology & therapeutics.

[75]  M. Pornin,et al.  [Phosphodiesterase inhibitors]. , 1990, Annales de cardiologie et d'angeiologie.

[76]  P. A. Friedman,et al.  Nifedipine serum concentrations following sublingual and oral doses. , 1986, International journal of clinical pharmacology, therapy, and toxicology.

[77]  J. Gustafsson,et al.  Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. , 1984, Endocrinology.

[78]  I. Hotson.  The avermectins: A new family of antiparasitic agents. , 1982, Journal of the South African Veterinary Association.

[79]  L. Siminovitch,et al.  The molecular basis of emetine resistance in chinese hamster ovary cells: Alteration in the 40S ribosomal subunit , 1977, Cell.

[80]  Ulrich Hollstein,et al.  Actinomycin. Chemistry and mechanism of action , 1974 .

[81]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .